GlassScriptPhysician profile
Mahmoud Othman
NPI 1508811456
$6,470.81
in general payments reported to CMS, 2019-2025
32 companies · $65.80 in 2025
The $65.80 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,502 · 2020: $479 · 2021: $384 · 2022: $581 · 2023: $2,720 · 2024: $740 · 2025: $65.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,007 · Travel and Lodging: $1,518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,007.49 |
| Travel and Lodging | $1,518.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $2,052.31 | 2020-2023 | Indigo System |
| Pinnacle, INC | $775.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $642.60 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $510.63 | 2021-2024 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $377.60 | 2019-2024 | Lifevest |
| Pfizer INC. | $312.98 | 2019-2023 | |
| Novo Nordisk INC | $196.64 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $181.63 | 2019-2024 | Repatha |
| Boston Scientific Corporation | $153.20 | 2019-2024 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.55 | 2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $136.61 | 2019-2023 | Wainua, Farxiga |
| Medtronic Vascular, INC. | $132.64 | 2019 | |
| Philips North America LLC | $98.62 | 2023 | |
| Janssen Pharmaceuticals, INC | $95.46 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $90.44 | 2020-2024 | Eliquis |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $88.07 | 2019 | |
| Amarin Pharma, INC. | $75.17 | 2020 | |
| Kestra Medical Technology Services, INC. | $74.36 | 2023-2024 | Assure Wcd |
| Abbott Laboratories | $45.86 | 2024 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Chiesi USA, INC. | $40.96 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $39.10 | 2019-2023 | Opsumit |
| Cleerly, INC. | $34.10 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Cvrx, INC. | $28.61 | 2021 | |
| Esperion Therapeutics, INC. | $27.33 | 2022-2023 | Nexletol |
| Kiniksa Pharmaceuticals, LTD. | $19.81 | 2023 | Arcalyst |
| Astellas Pharma US INC | $16.54 | 2019 | |
| Baxter Healthcare | $14.93 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Teleflex LLC | $14.37 | 2020 | |
| Scpharmaceuticals INC. | $13.55 | 2024 | |
| Gilead Sciences, INC. | $13.41 | 2019 | |
| Ekos Corporation | $12.69 | 2019 | |
| Tactile Systems Technology INC | $12.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahmoud Othman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.